Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT00137826
Phase
PHASE2
Status
Completed

Conditions

  • Mesothelioma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.
  • Bevacizumab — DRUG
    Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.

Study Details

The purpose of this study is to determine whether the combination of the investigational drugs Avastin and Tarceva are effective in patients with mesothelioma who have previously been treated with chemotherapy.

Key Dates

First listed
Aug 30, 2005
Start date
Feb 29, 2004
Status verified
Dec 2011
Primary completion
Mar 31, 2007
Completion
Jul 31, 2009

Study Design

Enrollment
37 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To determine the response to the combination of bevacizumab and erlotinib in previously treated malignant mesothelioma [ Time Frame: 3 years ]

Locations (3)

FacilityCityStateZIPSite coordinators
The University of ChicagoChicagoIllinois60637-
Dana-Farber Cancer InstituteBostonMassachusetts02115-
Massachusetts General HospitalBostonMassachusetts02114-

Find similar trials in Chicago, IL

By research site
The University of Chicago· Chicago, ILDana-Farber Cancer Institute· Boston, MAMassachusetts General Hospital· Boston, MA

Related Studies